{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:17:14Z","timestamp":1787937434230,"version":"build-2784847793"},"reference-count":36,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jacc.2026.03.063","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:20:08Z","timestamp":1779200408000},"page":"2580-2583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary Prevention for People Living With HIV"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4711-3956","authenticated-orcid":false,"given":"Markella V.","family":"Zanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Ribaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9876-4049","authenticated-orcid":false,"given":"Pamela S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K.","family":"Grinspoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jacc.2026.03.063_bib1","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacc.2026.03.063_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jacc.2026.03.063_bib3","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJMc2400870","article-title":"Trial update of pitavastatin to prevent cardiovascular events in HIV infection","volume":"390","author":"Grinspoon","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacc.2026.03.063_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0000000000001014","article-title":"Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care","volume":"73","author":"Marcus","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"10.1016\/j.jacc.2026.03.063_bib5","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","article-title":"HIV infection and the risk of acute myocardial infarction","volume":"173","author":"Freiberg","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1016\/j.jacc.2026.03.063_bib6","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacc.2026.03.063_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.122.057443","article-title":"Cardiovascular disease among persons living with HIV: New insights into pathogenesis and clinical manifestations in a global context","volume":"147","author":"Ntsekhe","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacc.2026.03.063_bib8","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2352-3018(17)30075-9","article-title":"Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial","volume":"4","author":"Aberg","year":"2017","journal-title":"Lancet HIV"},{"issue":"6","key":"10.1016\/j.jacc.2026.03.063_bib9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/QAD.0000000000001427","article-title":"Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV","volume":"31","author":"Toribio","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.jacc.2026.03.063_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ahj.2018.12.016","article-title":"Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)","volume":"212","author":"Grinspoon","year":"2019","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.jacc.2026.03.063_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/jamacardio.2023.5661","article-title":"Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: mechanistic substudy of the REPRIEVE randomized clinical trial","volume":"9","author":"Lu","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2026.03.063_bib12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jamacardio.2024.4115","article-title":"Pitavastatin, procollagen pathways, and plaque stabilization in patients with HIV: a secondary analysis of the REPRIEVE randomized clinical trial","volume":"10","author":"Kolossvary","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"25 Pt B","key":"10.1016\/j.jacc.2026.03.063_bib13","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.jacc.2026.03.063_bib14","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2026.03.063_bib15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/ciae422","article-title":"Pitavastatin is well tolerated with no detrimental effects on physical function","volume":"80","author":"Erlandson","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"14","key":"10.1016\/j.jacc.2026.03.063_bib16","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1097\/QAD.0000000000004306","article-title":"No evidence of pitavastatin effect on muscle area or density among people with HIV","volume":"39","author":"Erlandson","year":"2025","journal-title":"AIDS"},{"issue":"13","key":"10.1016\/j.jacc.2026.03.063_bib17","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1097\/QAD.0000000000004267","article-title":"No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV","volume":"39","author":"Erlandson","year":"2025","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.jacc.2026.03.063_bib18","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/S2352-3018(24)00345-X","article-title":"Statin effects on the incidence of major noncardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial","volume":"12","author":"Diggs","year":"2025","journal-title":"Lancet HIV"},{"issue":"11","key":"10.1016\/j.jacc.2026.03.063_bib19","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.7326\/ANNALS-24-00944","article-title":"Diabetes risk factors in people with HIV receiving pitavastatin versus placebo for cardiovascular disease prevention: a randomized trial","volume":"177","author":"Fitch","year":"2024","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.jacc.2026.03.063_bib20","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/S2352-3018(24)00276-5","article-title":"Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE","volume":"12","author":"Grinspoon","year":"2025","journal-title":"Lancet HIV"},{"issue":"4","key":"10.1016\/j.jacc.2026.03.063_bib21","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/cid\/ciaf207","article-title":"Incidence of statin initiation among people with and without hiv in the united states: A Prospective Observational Study","volume":"81","author":"Breger","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jacc.2026.03.063_bib22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/QAI.0000000000003083","article-title":"Statins utilization in adults with HIV: the treatment gap and predictors of statin initiation","volume":"91","author":"Coburn","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"10.1016\/j.jacc.2026.03.063_bib23","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.03.063_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(26)00031-7","article-title":"Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis","author":"Umbleja","year":"2026","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.jacc.2026.03.063_bib25","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1093\/cid\/ciaf542","article-title":"Risk assessment in a global CVD prevention cohort of people with HIV by PCE, PREVENT, and SCORE2","volume":"82","author":"Grinspoon","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"13","key":"10.1016\/j.jacc.2026.03.063_bib26","doi-asserted-by":"crossref","first-page":"F5","DOI":"10.1097\/QAD.0000000000004331","article-title":"Predicting Risk of Cardiovascular Disease Events (PREVENT) score accuracy among people with HIV in the multicenter CNICS cohort","volume":"39","author":"Durstenfeld","year":"2025","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.jacc.2026.03.063_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100968","article-title":"Coronary plaque in people with HIV vs non-HIV asymptomatic community and symptomatic higher risk populations","volume":"3","author":"Karady","year":"2024","journal-title":"JACC Adv"},{"issue":"5","key":"10.1016\/j.jacc.2026.03.063_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae234","article-title":"Coronary microvascular dysfunction is present among well treated asymptomatic persons with HIV and similar to those with diabetes","volume":"11","author":"Srinivasa","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"22","key":"10.1016\/j.jacc.2026.03.063_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029541","article-title":"Coronary microcirculatory dysfunction in people with HIV and its association with antiretroviral therapy","volume":"12","author":"Huck","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.jacc.2026.03.063_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy205","article-title":"Cardiac microvascular dysfunction in women living with HIV is associated with cytomegalovirus immunoglobulin G","volume":"5","author":"Knudsen","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"20","key":"10.1016\/j.jacc.2026.03.063_bib31","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.jacc.2020.03.025","article-title":"Evolocumab in HIV-infected patients with dyslipidemia: primary results of the randomized, double-blind BEIJERINCK study","volume":"75","author":"Boccara","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jacc.2026.03.063_bib32","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1097\/QAD.0b013e32833068e3","article-title":"Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients","volume":"23","author":"Chow","year":"2009","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.jacc.2026.03.063_bib33","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/cid\/ciab552","article-title":"Cardiovascular risk and health among people with human immunodeficiency virus (HIV) eligible for primary prevention: insights from the REPRIEVE trial","volume":"73","author":"Douglas","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jacc.2026.03.063_bib34","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1093\/cid\/ciaf210","article-title":"Factors affecting risk of cardiovascular disease (CVD) events in a global CVD prevention cohort of people with HIV","volume":"81","author":"Grinspoon","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"22","key":"10.1016\/j.jacc.2026.03.063_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/JCI196021","article-title":"Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV","volume":"135","author":"Kolossv\u00e1ry","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2026.03.063_bib36","article-title":"Relationship of Inflammatory, Cardiac, and Lipid Biomarkers to Cardiovascular Events in REPRIEVE","author":"Grinspoon","year":"2026","journal-title":"Abstract 117: Conference on Retroviruses and Opportunistic Infections"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726059097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726059097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:23:44Z","timestamp":1787934224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726059097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0735109726059097"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.03.063","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Prevention for People Living With HIV","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.03.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}